Global Nucleic Acid Testing Market 2016-2020
About Nucleic Acid Testing
Nucleic acid testing (NAT) is the process involved in the detection of viral DNAs and RNAs in blood samples of individuals. NAT or nucleic acid amplification test (NAAT) is one of the fastest growing segments in the in-vitro diagnostics market (IVD). There are different types of NAT techniques such as Polymerase chain reaction (PCR), Strand displacement amplification (SDA), Ligase chain reaction (LCR), Transcription-mediated amplification (TMA), Nucleic acid sequence based amplification (NASBA) and whole genome sequencing.
Technavio’s analysts forecast the global nucleic acid testing market to grow at a CAGR of 9.96% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global nucleic acid testing market for 2016-2020. To calculate the market size, the report presents the vendor landscape and a corresponding detailed analysis of the top vendors operating in the market.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Nucleic Acid Testing Market 2016-2020
Technavio recognizes the following companies as the key players in the global nucleic acid testing market: Abbott Laboratories, Roche Molecular Systems, Siemens Healthineers, Hologic, and Qiagen.
Other prominent vendors in the market are: Accriva Diagnostics, Acon Laboratories, Affymetrix, Ahram Biosystem, Asuragen, Biocartis, Bio-Rad Laboratories, Cepheid, DiagCor, EKF Diagnostics, Erba Diagnostics, and Randox Laboratories.
Commenting on the report, an analyst from Technavio’s team said: “One of latest trends in the market is next generation sequencing. Next generation sequencing (NGS) is the game changing trend in the IVD market due to its wide range of methods being readily available to the researchers. This sequencing method helps in answering any question about the genome, epitome and transcriptome of an organism. The process of sequencing has emerged as a technology boom for the clinical diagnosis field. It enables doctors and researchers in the detection of various infectious diseases such as Chlamydia trachomatis/Neisseria gonorrhoeae infection and pulmonary tuberculosis. Some of the most common NGS methods trending in the molecular diagnosis field are exome sequencing, total RNA and mRNA sequencing.”
According to the report, one of the primary drivers in the market is genome engineering and gene editing on rise. Genome engineering is one of the new technologies in the IVD market, which is gaining quick acceptance and serve beneficial in transforming healthcare system. Genome sequencing in molecular diagnostics helps in the detection of most complex diseases such as cancer and HIV. The next generation sequencing is one of the lucrative investments for pharmaceutical companies. The market is witnessing higher investment in the genomics research, government funding for gene therapy and other related techniques. There is a rise in the demand for gene editing for the alteration of genetic framework of an organism. This helps in facilitating the removal of defective gene and infusing corrective one resuming the genetic framework of body. With the use of technologies such as CRISPR and antisense technology, the researchers aim to change the prevailing healthcare scenario. Along with the improvement in blood screening process through NAT, the researchers aim to use the technology of gene editing for the treatment of incurable diseases such as HIV and cancer.
Further, the report states that one major challenge in the market is risks associated with molecular diagnosis. With the advent of new technologies in the market, the process of clinical diagnostics has undergone a transformation. The NAT blood screening process has served beneficial in determining infectious agents. However, the molecular diagnosis process involved in the screening of infectious diseases and genetic variation have some risks associated with it. The standardization of the system makes the process of optimization a tedious task. But, it plays a key role in maintaining the accuracy of results. The diagnostic systems lack the feature for determining sample type and volume. This acts a constraint in development of efficient NAT screening systems and integration of systems. There is a lack in the integration of diagnostic assays along with the next generation screening systems. The improved sensory system for biosensors is an unmet demand of the molecular diagnostics. The sensitivity for biosensors will ensure accuracy and eliminate enzymatic in-vitro amplification process. These risks divert the growth of the market.
Abbott Laboratories, Roche Molecular Systems, Siemens Healthineers, Hologic, Qiagen, Accriva Diagnostics, Acon Laboratories, Affymetrix, Ahram Biosystem, Asuragen, Biocartis, Bio-Rad Laboratories, Cepheid, DiagCor, EKF Diagnostics, Erba Diagnostics, Randox Laboratories.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook